logo-loader

Geneius Biotechnology's T-cell therapy product in preclinical testing to treat variety of cancers

Published: 14:10 13 Nov 2018 EST

Geneius Biotechnology Inc CEO Alfred Slanetz tells Proactive Investors the company is focused on the discovery and clinical development of adoptive T- cell therapy products to treat cancer.

Slanetz says the biotech's lead product candidate is currently in preclinical testing for gastric and nasopharyngeal cancers.

Geneius is privately held but the CEO will look to take the company public by the end of 2020.

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

59 minutes ago